Mayne Pharma Group Limited

MYX

AU000000MYX0

Pharmaceuticals

Delayed Australian S.E. Other stock markets 02:10:52 2024-04-18 am EDT			5-day change	1st Jan Change
6.75 ^AUD	+1.35%		-5.06%	+9.76%

Feb. 26	Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15%	MT
Feb. 25	Transcript : Mayne Pharma Group Limited, H1 2024 Earnings Call, Feb 26, 2024

Mayne Pharma : Estelle Oral Contraceptive Now Available In the United States

June 22, 2021 at 10:05 am EDT

Adelaide, Australia and Liege, Belgium: Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the US commercial launch of Estelle under the trademark Nextstellis (3 mg drospirenone and 14.2 mg estetrol (E4) tablets), a new oral contraceptive with a novel estrogen having a unique mechanism of action.

Contact:

Tel: +32 (0)4 349 28 22

Fax: +32 (0)4 349 28 21

Email: info@mithra.com

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	ESTELLE HOLDINGS CO.,LTD.	646 JPY	0.00%	-0.62%	43.77M
	MITHRA PHARMACEUTICALS S.A.	0.233 EUR	+5.67%	+1.75%	16.21M

Latest news about Mayne Pharma Group Limited

Mayne Pharma Group Swings to Loss in Fiscal H1 Despite Revenue Growth; Shares Jump 15%	Feb. 25	MT
Transcript : Mayne Pharma Group Limited, H1 2024 Earnings Call, Feb 26, 2024	Feb. 25
Mayne Pharma Group Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 25	CI
Mithra Pharmaceuticals Exits Stake in Mayne Pharma	Feb. 16	MT
An undisclosed buyer acquired a 5.06% stake in Mayne Pharma Group Limited from Mithra Pharmaceuticals SA for AUD 21 million	Feb. 14	CI
Transcript : Mayne Pharma Group Limited Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM	Jan. 11
Mayne Pharma Group Limited Approves Election of Anne Lockwood	Nov. 29	CI
Transcript : Mayne Pharma Group Limited - Shareholder/Analyst Call	Nov. 29
Mithra Pharmaceuticals Obtains US Patent for Contraceptive Pill	Nov. 07	MT
Mayne Pharma Gets Additional US Patent for Contraceptive	Nov. 06	MT
Mayne Pharma Gets Go-Ahead for Resignation of EY as Auditor	Nov. 03	MT
Transcript : Mayne Pharma Group Limited - Shareholder/Analyst Call	23-10-17
Mayne Pharma Acquires Dermatological Medication	23-09-26	MT
Mayne Pharma Group Limited completed the acquisition of Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC.	23-09-24	CI
Mayne Pharma Group Limited agreed to acquire Assets Related To RHOFADE® (Oxymetazoline Hydrochloride) Cream 1% from EPI Health, LLC for $8 million.	23-09-06	CI
Australian Shares Rebound Ahead of Central Bank Policy Meeting	23-09-04	MT
Mayne Pharma Group Purchasing Global Rights to Topical Treatment RHOFADE	23-09-04	MT
Transcript : Mayne Pharma Group Limited, 2023 Earnings Call, Aug 31, 2023	23-08-30
Tranche Update on Mayne Pharma Group Limited's Equity Buyback Plan announced on May 10, 2023.	23-08-30	CI
Mayne Pharma Group Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Lupin Gets US FDA Nod for Doxycycline Hyclate Delayed-Release Tablets	23-08-14	MT
Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023	23-07-26	CI
Mithra Pharmaceuticals Cuts Mayne Pharma Group Stake to 4.96%	23-06-19	MT
An unknown buyer acquired a 4.97% stake in Mayne Pharma Group Limited from Estetra Srl for AUD 16 million.	23-06-15	CI
Transcript : Mayne Pharma Group Limited - Special Call	23-05-09

Chart Mayne Pharma Group Limited

Duration

Period

More charts

Company Profile

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company. The Company is focused on commercializing generic pharmaceuticals. The Company operates through three segments: International, Branded Products Division (BPD) and Portfolio Products Division (PPD). Its International segment manufactures and sells branded and generic pharmaceutical product globally and the provision of contract development and manufacturing services to third party customers. The BPD segment distributes medically differentiated specialty products in United States. The PPD segment distributes established products (branded and generic) in the United States on a portfolio basis. The Company's products include Doxycycline Capsules, Oxycodone IR Tablets, Erythromycin Capsules and others.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q4 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Mayne Pharma Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.75 AUD

Average target price

7.035 AUD

Spread / Average Target

+4.22%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
MAYNE PHARMA GROUP LIMITED	+9.76%	347M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.40%	44.1B
OTSUKA HOLDINGS CO., LTD.	+16.45%	21.97B
CIPLA LIMITED	+8.10%	13.27B
SANDOZ GROUP AG	+6.06%	13.22B
ZYDUS LIFESCIENCES LIMITED	+35.95%	11.36B
ONO PHARMACEUTICAL CO., LTD.	-8.84%	7.07B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+7.71%	5.23B

Generic Pharmaceuticals

Mayne Pharma Group Limited

Equities

MYX

AU000000MYX0

Pharmaceuticals

Mayne Pharma : Estelle Oral Contraceptive Now Available In the United States

Stocks mentioned in the article

EPS Revisions